NeuroAiD1 is a Traditional Chinese Medicine drug marketed in China for approved-indication of cerebral infarction's functional and neurological deficits, i.e. helping patient recover from their disabilities after a stroke.

The registration in China was supported by the results obtained from initial double-blind control randomized studies performed in China from 1999 to 2001 on 605 ischemic stroke patients at restoration stage. These studies evidenced NeuroAiD's efficacy to improve stroke patients' ability to recover even when started several weeks after the stroke onset. Given its unique profile in attending stroke patients' needs with a very safe profile, NeuroAiD presents a strong opportunity to fill a gap in stroke patients' treatment in the West.

In China, more than 150,000 patients are treated yearly with this drug.


  1. NeuroAiD is the trade name for Danqi Jiaonang in several countries outside China.